)
Overview
<ul>
<li>US rare disease drug developer’s Q4 net loss widened yr/yr as expenses rose</li>
<li>General and administrative expenses increased due to workforce expansion and commercial planning</li>
<li>Company achieved key regulatory milestones for MOLBREEVI in US and Europe</li>
</ul>
Outlook
<ul>
<li>Savara expects FDA PDUFA decision on MOLBREEVI by August 22, 2026</li>
</ul>
Result Drivers
<ul>
<li>REGULATORY COSTS - Higher research and development expenses were primarily due to regulatory affairs and quality assurance activities related to the MOLBREEVI BLA submission</li>
<li>COMMERCIAL PLANNING - General and administrative expenses rose due to workforce expansion and commercial activities ahead of potential MOLBREEVI launch Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>Q4 EPS -$0.13</h3>
Q4 Net -$32.24
Income mln
<h3>Q4 -$33.42</h3>
Income mln
from
Operatio
ns
<h3>Q4 $33.42</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 8 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Savara Inc is $10.25, about 92.7% above its March 12 closing price of $5.32 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

SVRA

SBIO

LABU

Reuters

Savara

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Savara Q4 net loss widens as expenses rise